单剂静脉氯胺酮对自杀意念影响的个体参与者数据荟萃分析
该系统综述与个体参与者数据荟萃分析纳入10项对照研究、167例基线存在自杀意念的参与者,比较单剂氯胺酮与安慰剂或咪达唑仑。结果显示氯胺酮在给药后1天内显著降低自杀意念,效应量中等至较大,并持续至1周;校正抑郁症状变化后效应仍显著。
要点
- 单剂氯胺酮在1天内降低自杀意念,效果持续至1周
- 效应量中等至较大,校正抑郁症状变化后仍显著
- 临床实施前需进一步研究长期安全性与降低自杀风险的效果
核心结论
- 单剂静脉氯胺酮可在抑郁伴自杀意念患者中于1天内快速降低自杀意念,效果持续至1周,且部分独立于对心境的作用。
研究设计与样本
- 系统综述与个体参与者数据荟萃分析,数据来自11项对照研究中的10项,对照为生理盐水或咪达唑仑。
- 分析仅纳入基线存在自杀意念的参与者,共167例,采用一阶段个体参与者数据混合效应多层一般线性模型。
主要发现
- 氯胺酮在给药后1天内即显著降低自杀意念,临床医生评定与自评量表结果一致。
- 各时间点效应量为中等至较大(Cohen's d=0.48-0.85)。
- 敏感性分析显示氯胺酮对MADRS、HAM-D和QIDS-SR的自杀条目有显著获益,但对BDI无显著获益。
- 校正同期抑郁症状严重度变化后,氯胺酮对自杀意念的效应仍显著。
关键数值与推荐
- 主要结局为临床医生评定(MADRS或HAM-D)与自评(QIDS-SR或BDI)量表中的自杀条目,评估至给药后1周。
- 效应量Cohen's d=0.48-0.85。
临床怎么用
- 结果提示单剂氯胺酮可用于抑郁伴自杀意念患者的快速短期干预,但需在进一步确认长期安全性与降低自杀风险疗效后再临床推广。
局限性
- 需在跨诊断样本中进一步试验以确认氯胺酮对自杀意念的特异效应。
- 临床实施前仍需研究氯胺酮的长期安全性及其降低自杀风险的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Suicide is a public health crisis with limited treatment options. The authors conducted a systematic review and individual participant data meta-analysis examining the effects of a single dose of ketamine on suicidal ideation. METHOD: Individual participant data were obtained from 10 of 11 identified comparison intervention studies that used either saline or midazolam as a control treatment. The analysis included only participants who had suicidal ideation at baseline (N=167). A one-stage, individual participant data, meta-analytic procedure was employed using a mixed-effects, multilevel, general linear model. The primary outcome measures were the suicide items from clinician-administered (the Montgomery-Åsberg Depression Rating Scale [MADRS] or the Hamilton Depression Rating Scale [HAM-D]) and self-report scales (the Quick Inventory of Depressive Symptomatology-Self Report [QIDS-SR] or the Beck Depression Inventory [BDI]), obtained for up to 1 week after ketamine administration. RESULTS: Ketamine rapidly (within 1 day) reduced suicidal ideation significantly on both the clinician-administered and self-report outcome measures. Effect sizes were moderate to large (Cohen's d=0.48-0.85) at all time points after dosing. A sensitivity analysis demonstrated that compared with control treatments, ketamine had significant benefits on the individual suicide items of the MADRS, the HAM-D, and the QIDS-SR but not the BDI. Ketamine's effect on suicidal ideation remained significant after adjusting for concurrent changes in severity of depressive symptoms. CONCLUSIONS: Ketamine rapidly reduced suicidal thoughts, within 1 day and for up to 1 week in depressed patients with suicidal ideation. Ketamine's effects on suicidal ideation were partially independent of its effects on mood, although subsequent trials in transdiagnostic samples are required to confirm that ketamine exerts a specific effect on suicidal ideation. Additional research on ketamine's long-term safety and its efficacy in reducing suicide risk is needed before clinical implementation.
引用
- Wilkinson ST, Ballard ED, Bloch MH, et al. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. Am J Psychiatry. 2017. PMID: 28969441. doi:10.1176/appi.ajp.2017.17040472
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。